2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

2:30PM-4:00PM: Abstract Number: 850

Long Term Efficacy of Cartilage Repair Induced By scSOX9 in Situ with Bone Marrow-Derived Mesenchymal Stem Cells

3S085 ACR Abstract: Osteoarthritis & Joint Biology–Basic Science (846–850)

2:30PM-4:00PM: Abstract Number: 904

Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry

3S090 ACR Abstract: Vasculitis–ANCA-Assocd (904–909)

2:30PM-4:00PM: Abstract Number: 902

Longitudinal Trends in Clinical Disease Features after Myeloablative Autologous Stem-Cell Transplantation or Cyclophosphamide in Severe Scleroderma

3S089 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical I: Clinical Trials I (898–903)

2:30PM-4:00PM: Abstract Number: 858

Measuring Cognitive Load during Arthrocentesis Training: Our Initial Experience

3S081 ACR Abstract: Education (857–862)

2:30PM-4:00PM: Abstract Number: 845

New Insights in Lupus Dermatitis: Differential Regulation and Roles of Tissue-Resident Dendritic Cell Subsets in the Pathogenesis of Autoimmune Skin Inflammation

3S080 ACR Abstract: Cytokines & Cell Trafficking (840–845)

2:30PM-4:00PM: Abstract Number: 870

Patient-Reported Burden of Gout in 2017 from the United States

3S083 ACR Abstract: Metabolic & Crystal Arthropathies: Comorbidities & Outcomes (869–874)

2:30PM-4:00PM: Abstract Number: 866

Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy

3S082 ACR Abstract: Imaging of Rheumatic Diseases I: MRI & CT (863–868)

2:30PM-4:00PM: Abstract Number: 896

Pharmacogenomics Study of Predicting Response of TNF Blocker and Medical Image Progression in Chinese Han Ankylosing Spondylitis Population

3S088 ACR Abstract: Spondyloarthritis Incl PsA–Clinical I: Axial SpA Epidemiology (892–897)

2:30PM-4:00PM: Abstract Number: 882

Predictors of Chronic Kidney Disease in US Veterans with Rheumatoid Arthritis

3S086 ACR Abstract: RA–DX, Manifestations, & Outcomes I: Other Co-Morbidities (880–885)

2:30PM-4:00PM: Abstract Number: 897

Prevalence of Inflammatory and Chronic Changes Suggestive of Axial Spondyloarthritis in Magnetic Resonance Images of the Axial Skeleton in Individuals < 45 Years in the General Populationas Part of a Large Community Study (SHIP)

3S088 ACR Abstract: Spondyloarthritis Incl PsA–Clinical I: Axial SpA Epidemiology (892–897)

2:30PM-4:00PM: Abstract Number: 874

Preventing a Large Majority of Incident Gout Cases By Modifying Key Risk Factors: Findings from a Prospective Cohort of 44,629 Men over 26 Years

3S083 ACR Abstract: Metabolic & Crystal Arthropathies: Comorbidities & Outcomes (869–874)

2:30PM-4:00PM: Abstract Number: 884

Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study

3S086 ACR Abstract: RA–DX, Manifestations, & Outcomes I: Other Co-Morbidities (880–885)

2:30PM-4:00PM: Abstract Number: 903

Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)

3S089 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical I: Clinical Trials I (898–903)

2:30PM-4:00PM: Abstract Number: 913

Risk Factors for Knee Pain Exacerbation on Walking: A within-Person Knee-Matched Study

3S093 ACR/ARHP Abstract: Epidemiology & Pub Health (910–915)

2:30PM-4:00PM: Abstract Number: 880

Serum Cytokine and Chemokine Concentrations Predict Incident Cancer in US Veterans with Rheumatoid Arthritis

3S086 ACR Abstract: RA–DX, Manifestations, & Outcomes I: Other Co-Morbidities (880–885)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].